围手术期化疗对胰腺腺鳞癌的影响
本研究回顾性分析2001至2022年间3个高容量中心收治的168例切除的胰腺腺鳞癌患者,比较新辅助化疗与直接手术的预后。
核心结论
- 切除的胰腺腺鳞癌总体预后仍差,新辅助化疗未见明显获益,辅助治疗可能具有保护作用但需进一步研究。
研究设计与样本
- 回顾性队列研究,纳入2001至2022年间3个高容量中心收治的168例切除的胰腺腺鳞癌患者。
主要发现
- 新辅助化疗组(41例,24%)与直接手术组(127例,76%)人口学和TNM分期相似。
- 按治疗方式分层的中位总生存期:未化疗4个月,仅新辅助化疗8个月,仅辅助治疗24个月,新辅助加辅助治疗17个月。
临床怎么用
- 对于可切除的胰腺腺鳞癌,新辅助化疗的获益有限,应审慎选择。
- 术后辅助治疗可能改善生存,建议优先考虑。
- 年龄≥65岁患者预后较差,需加强围手术期管理。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- 无复发生存期数据仅来自69例患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic adenosquamous carcinoma has historically poor overall survival, and the impact of perioperative chemotherapy remains unclear. We aimed to evaluate the impact of various chemotherapy regimens in patients with resected adenosquamous carcinoma. METHODS: Patients with resected adenosquamous carcinoma were identified from 3 high-volume programs between 2001 and 2022. We analyzed their clinicopathologic data and used Kaplan-Meier survival curves to assess the median overall survival and recurrence-free survival with 95% confidence intervals. Prognostic factors were assessed with a multivariable Cox-regression model adjusting for resectability status and Clavien-Dindo complications. RESULTS: Among 168 patients, cohorts of neoadjuvant chemotherapy (41, 24%) and upfront surgery (127, 76%) showed similar demographics and TNM staging. The median overall survival was shorter in the neoadjuvant chemotherapy cohort compared with the upfront surgery cohort (13 vs 21 months, P = .133). Median overall survival by treatment approach was no chemotherapy (4 months), only neoadjuvant chemotherapy (8 months), only adjuvant therapy (24 months), and both neoadjuvant chemotherapy and adjuvant therapy (17 months). Recurrence-free survival data (69 patients) showed upfront surgery had significantly longer recurrence-free survival compared with neoadjuvant chemotherapy (18 months vs 5 months, P = .046). Multivariable analysis showed adjuvant therapy was associated with improved overall survival (hazard ratio, 0.27; P < .001), whereas age ≥65 (hazard ratio, 1.79, P = .030) was associated with worse overall survival. CONCLUSION: The outcomes of resected adenosquamous carcinoma remain poor. Patients receiving neoadjuvant chemotherapy exhibited shorter recurrence-free survival and median overall survival, suggesting minimal benefit of neoadjuvant chemotherapy in treating this aggressive cancer. Meanwhile, adjuvant therapy appears to be protective but requires further investigation.
引用
- Campbell BA, Habib JR, Kinny-Köster B, et al. The impact of perioperative chemotherapy in patients with pancreatic adenosquamous carcinoma. Surgery. 2025. PMID: 40812072. doi:10.1016/j.surg.2025.109611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。